分析达格列净、维格列汀、阿卡波糖治疗新诊断T2DM的效果  

Analysis of the effect of dapagliflozin,vildagliptin,and acarbose in the treatment of newly diagnosed T2DM

作　　者：王晓立 李硕[1] WANG Xiao-li;LI Shuo(Central Dispensing Station,Heze Municipal Hospital,Heze 274000,China)

机构地区：[1]菏泽市立医院中心摆药站,274000

出　　处：《中国现代药物应用》2025年第7期31-35,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析新诊断2型糖尿病(T2DM)行不同药物治疗的效果。方法以100例新诊断T2DM患者为样本,摸球后分组为一组(30例)、二组(30例)和三组(40例)。一组行达格列净治疗,二组行维格列汀治疗,三组行阿卡波糖治疗。比较三组治疗效果、不良反应发生情况及治疗前后的血糖指标水平、胰岛功能指标水平、骨代谢指标水平。结果一组、二组、三组治疗总有效率分别为96.67%、93.33%、90.00%,但组间两两比较差异不明显(P>0.05)。治疗后,一组、二组、三组血糖指标水平均较治疗前降低(P<0.05),但一组、二组、三组血糖指标水平比较差异不明显(P>0.05)。治疗后,一组、二组、三组胰岛β细胞功能指数(HOMA-β)相比治疗前均升高,胰岛素抵抗指数(HOMA-IR)相比治疗前均降低(P<0.05),但一组、二组、三组胰岛功能指标水平比较差异不明显(P>0.05)。治疗后,一组、二组、三组血清Ⅰ型胶原羧基末端肽(β-CTX)相比治疗前均升高,Ⅰ型前胶原氨基末端肽(PⅠNP)相比治疗前均降低(P<0.05),且一组β-CTX(628.03±16.21)pg/ml高于二组的(589.76±15.44)pg/ml和三组的(588.23±14.71)pg/ml,PⅠNP(39.64±3.15)ng/ml低于二组的(45.22±1.71)ng/ml和三组的(45.62±1.09)ng/ml(P<0.05),但二组、三组骨代谢指标水平比较差异不明显(P>0.05)。一组、二组、三组不良反应发生率分别为6.67%、3.33%、10.00%,但组间两两比较差异不明显(P>0.05)。结论对新诊断T2DM患者使用阿卡波糖、维格列汀、达格列净治疗均有明显作用,其血糖、胰岛功能调节效果均比较明显,而前两种药物对骨代谢的影响小,在防范骨质疏松方面更有价值。Objective To analyze the effect of dapagliflozin,vildagliptin,and acarbose in the treatment of newly diagnosed type 2 diabetes mellitus(T2DM).Methods 100 newly diagnosed T2DM patients were divided into group 1(30 cases),group 2(30 cases),and group 3(40 cases)by ball-touching method.Group 1 was treated with dapagliflozin,group 2 was treated with vildagliptin,and group 3 was treated with acarbose.The treatment effect,occurrence of adverse reactions,blood glucose index,islet function index and bone metabolism index before and after treatment were compared among the three groups.Results The total effective rates of group 1,group 2 and group 3 were 96.67%,93.33%and 90.00%,but there was no significant difference in pairwise comparison among groups(P>0.05).After treatment,the level of blood glucose index in group 1,group 2 and group 3 was lower than that before treatment(P<0.05),but there was no significant difference in the level of blood glucose index in group 1,group 2 and group 3(P>0.05).After treatment,isletβcell function index(HOMA-β)of group 1,group 2 and group 3 was increased compared with before treatment,and insulin resistance index(HOMA-IR)was decreased compared with before treatment(P<0.05),but there was no significant difference in islet function index of group 1,group 2 and group 3(P>0.05).After treatment,the serumβ-Carboxyl terminal peptide(β-CTX)was increased,and procollagen typeⅠaminoterminal peptide(PⅠNP)was decreased in group 1,group 2 and group 3 compared with before treatment(P<0.05).Group 1 had a higherβ-CTX of(628.03±16.21)pg/ml than(589.76±15.44)pg/ml in group 2 and(588.23±14.71)pg/ml in group 3;group 1 had a lower PⅠNP of(39.64±3.15)ng/ml than(45.22±1.71)ng/ml in group 2 and(45.62±1.09)ng/ml in group 3(P<0.05).However,there was no significant difference in the level of bone metabolism indexes between group 2 and group 3(P>0.05).The incidence of adverse reactions in group 1,group 2 and group 3 were 6.67%,3.33%and 10.00%,but there was no significant difference in pairwise comparis

关 键 词：新诊断 2型糖尿病 阿卡波糖 达格列净 维格列汀 血糖水平 骨代谢 

分 类 号：R587.1[医药卫生—内分泌]